Tagged with Lundbeck

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

India The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to shutter its Indian operations, Bharat Biotech’s connection to the world’s first malaria vaccine, and the two million missing workers within…

Denmark Since joining Danish neuroscience specialist Lundbeck as its global CEO in 2018, South African Deborah Dunsire has focused on “revitalising and refreshing” the firm’s pipeline, which had seen several failures in the preceding years. In an exclusive recent conversation with PharmaBoardroom, Dunsire explains the strategy she has put in place…

Denmark Speaking exclusively to PharmaBoardroom, Lundbeck’s global CEO Deborah Dunsire describes the progress in the strategy she put in place to “revitalise and refresh” the Danish firm’s pipeline upon taking the role three years ago. Following two recent acquisitions, Lundbeck now has a much broader focus across neuroscience including areas for…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

USA The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their vital role leading operations in the world’s most innovative and lucrative pharma market, translating global cultures to a US reality, and the challenges of attracting and retaining…

USA PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted the long-term damage COVID-19 is causing to the general mental health of society, and how Lundbeck is well-positioned to address this in North America.   As the global pandemic rages on,…

USA Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s specialty portfolio in the US market, the challenges of working in the CNS space, and how the company is adapting to the problems posed by the COVID-19 pandemic.  …

Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…

Mexico Sara Montero, managing director of Lundbeck Mexico, Central America and Andean countries since January 2020, explains her key priorities and the importance of the region for Lundbeck, highlights the current situation for mental illness in Latin America (LatAm) and outlines her objective to bring innovative treatments to Mexican patients.  …

Sweden Richard Wikner, country manager of Lundbeck Sweden, explains the affiliate’s strategic significance to the research-based company and its role in raising awareness about mental illnesses in the region, in addition to the company’s mission of striving to help patients return to their normal lives following depression.   [Sweden] still remains…

China China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being rolled out, it can be challenging for large organizations with headquarters located in slower-paced mature markets to adapt to China’s…